List of Studies ( Metabolite:13,14-Dihydro-15-keto-PGF2alpha)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | ng/g tissue |
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | ng/g tissue |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | ng/mL |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | ng/mL |
| ST000004 | AN000004 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | nM | |
| ST000916 | AN001491 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
| ST000917 | AN001497 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | nM |
| ST001206 | AN002008 | Effects of cold exposure on serum lipidomic in mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
| ST001207 | AN002009 | Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
| ST001213 | AN002024 | Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
| ST001214 | AN002025 | Lipidommics in the serum of human subjects | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
| ST001215 | AN002026 | Effect of Mirabegron Treatment on serum lipidome | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
| ST000915 | AN001485 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
| ST000046 | AN000079 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
